United States HR 6155: To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.

Status: Introduced in House (as of 2020-03-09)

State: United States · Session: 116 · Bill: HR 6155

Subjects: Drug safety, medical device, and laboratory regulation, Licensing and registrations, Prescription drugs

Sponsors: Glenn Grothman

View United States HR 6155 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.